Simona Stan's questions to Ascendis Pharma A/S (ASND) leadership • Q3 2024
Question
Speaking for Derek Archila, Simona Stan asked about payer progress for SKYTROFA's adult indication and whether the YORVIPATH launch would require medical exceptions for access.
Answer
Jan Mikkelsen, President and CEO, noted that SKYTROFA's market access has improved and the strategy remains focused on its high-value position, with a net value 3x that of daily growth hormone. For YORVIPATH, he expressed high confidence in reimbursement, stating that since it is on-label, aligns with guidelines, and is the only approved product, access should be straightforward.